XML 76 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2022
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:              
Research and development $ 4,123,538 $ 4,033,963 $ 2,149,641 $ 6,183,604 $ 10,307,142 $ 16,515,543 $ 8,479,031
General and administrative 2,361,299 1,938,447 3,104,071 5,042,518 7,403,817 8,995,736 6,058,190
Total operating expenses 6,484,837 5,972,410 5,253,712 11,226,122 17,710,959 25,511,279 14,537,221
Operating loss (6,484,837) (5,972,410) (5,253,712) (11,226,122) (17,710,959) (25,511,279) (14,537,221)
Other income:              
Interest income 52,886 36,024 19,649 55,673 108,559 182,712 13,335
Grant income             36,754
Total other income 52,886 36,024 19,649 55,673 108,559 182,712 50,089
Loss before income taxes (6,431,951) (5,936,386) (5,234,063) (11,170,449) (17,602,400) (25,328,567) (14,487,132)
Income Tax Expense (Benefit)          
Net loss $ (6,431,951) $ (5,936,386) $ (5,234,063) $ (11,170,449) $ (17,602,400) $ (25,328,567) $ (14,487,132)
Basic loss per common share $ (0.79) $ (0.73) $ (0.64) $ (1.37) $ (2.16) $ (3.10) $ (1.90)
Diluted loss per common share $ (0.79) $ (0.73) $ (0.64) $ (1.37) $ (2.16) $ (3.10) $ (1.90)
Weighted average number of common shares outstanding, basic 8,163,923 8,163,923 8,157,445 8,160,702 8,161,787 8,162,326 7,626,278
Weighted average number of common shares outstanding, diluted 8,163,923 8,163,923 8,157,445 8,160,702 8,161,787 8,162,326 7,626,278
As Reported              
Operating expenses:              
Research and development $ 5,313,033 $ 6,815,708 $ 2,809,791 $ 9,625,499 $ 14,938,532    
General and administrative 2,361,299 1,938,447 3,104,071 5,042,518 7,403,817    
Total operating expenses 7,674,332 8,754,155 5,913,862 14,668,017 22,342,349    
Operating loss (7,674,332) (8,754,155) (5,913,862) (14,668,017) (22,342,349)    
Other income:              
Interest income 52,886 36,024 19,649 55,673 108,559    
Total other income 52,886 36,024 19,649 55,673 108,559    
Loss before income taxes (7,621,446) (8,718,131) (5,894,213) (14,612,344) (22,233,790)    
Net loss $ (7,621,446) $ (8,718,131) $ (5,894,213) $ (14,612,344) $ (22,233,790)    
Basic loss per common share $ (0.93) $ (1.07) $ (0.72) $ (1.79) $ (2.72)    
Diluted loss per common share $ (0.93) $ (1.07) $ (0.72) $ (1.79) $ (2.72)    
Weighted average number of common shares outstanding, basic 8,163,923 8,163,923 8,157,445 8,160,702 8,161,787    
Weighted average number of common shares outstanding, diluted 8,163,923 8,163,923 8,157,445 8,160,702 8,161,787    
Restatement Impacts              
Operating expenses:              
Research and development $ (1,189,495) $ (2,781,745) $ (660,150) $ (3,441,895) $ (4,631,390)    
Total operating expenses (1,189,495) (2,781,745) (660,150) (3,441,895) (4,631,390)    
Operating loss 1,189,495 2,781,745 660,150 3,441,895 4,631,390    
Other income:              
Loss before income taxes 1,189,495 2,781,745 660,150 3,441,895 4,631,390    
Net loss $ 1,189,495 $ 2,781,745 $ 660,150 $ 3,441,895 $ 4,631,390